Summit Therapeutics to showcase HARMONi-GI1 trial at ESMO 2026
Summit Therapeutics said data from its Phase III HARMONi-GI1 trial in China, featuring ivonescimab plus chemotherapy versus durvalumab plus chemotherapy, will be featured at the Presidential Symposium at ESMO 2026.